Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Change in Receivables (2018 - 2025)

Historic Change in Receivables for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to -$24.1 million.

  • TransMedics' Change in Receivables fell 37381.79% to -$24.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.7 million, marking a year-over-year decrease of 13308.86%. This contributed to the annual value of $34.3 million for FY2024, which is 146.08% up from last year.
  • As of Q3 2025, TransMedics' Change in Receivables stood at -$24.1 million, which was down 37381.79% from -$37.5 million recorded in Q2 2025.
  • Over the past 5 years, TransMedics' Change in Receivables peaked at $44.1 million during Q1 2025, and registered a low of -$37.5 million during Q2 2025.
  • Moreover, its 5-year median value for Change in Receivables was $5.4 million (2022), whereas its average is $3.8 million.
  • As far as peak fluctuations go, TransMedics' Change in Receivables soared by 89554.03% in 2022, and later plummeted by 485614.27% in 2025.
  • TransMedics' Change in Receivables (Quarter) stood at $1.8 million in 2021, then skyrocketed by 197.85% to $5.4 million in 2022, then plummeted by 47.71% to $2.8 million in 2023, then surged by 178.15% to $7.8 million in 2024, then tumbled by 407.97% to -$24.1 million in 2025.
  • Its Change in Receivables stands at -$24.1 million for Q3 2025, versus -$37.5 million for Q2 2025 and $44.1 million for Q1 2025.